Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Medicine, a distributor and developer of ethical and over-the-counter drugs, in the People's Republic of China, has obtained the exclusive rights to sell 2,300 products included in the company's current catalogue.
Subscribe to our email newsletter
The company won the exclusive rights through an on-line bidding system called the “Guangdong Sunshine Medicine Public Internet Bidding System’. Among the 2,300 products that the Company has maintained exclusive rights to sell, four were developed by China Medicine. They include Ozagrel, a powder-injection that is used for treatment of acute myocardial infarction; Bumetanide, an injection used for treatment of diuretic and chronic kidney failure; Levocarnitine, an injection used for the treatment of coronary heart disease; and Ji Xue Gan Pian, a tablet which is used for the treatment of cuts from surgery and skin disease.
China Medicine believes that securing and maintaining the rights to sell the drugs previously included in its portfolio will help to increase revenues going forward since the company has already gone through the introductory phase, which is typically a period of slower sales when new products are advertised and marketed.
Senshan Yang, chairman and CEO of China Medicine, said: “We will be selling our products to hospitals throughout Guangdong Province through an online drug sales system.”